Abstract
Drug makers’ payments to doctors have helped to drive the growing use of gabapentinoids, says a research letter in JAMA Internal Medicine .1 The frequent off-label prescribing of this class...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
